Predictive Biosciences' advisors are internationally renowned scientific and clinical leaders providing guidance to the applied research and business teams at Predictive Biosciences.

• Bruce Zetter (Co-Founder and Chairman, Scientific Advisory Board), Harvard Medical School and Children's Hospital Boston
• Marsha Moses (Co-Founder), Harvard Medical School and Children's Hospital Boston
• Martin Fleisher, Memorial Sloan-Kettering Cancer Center
• Kevin Loughlin, Brigham and Women’s Hospital
• John Reed, Burnham Institute for Medical Research

Bruce R. Zetter, Ph.D. (Co-Founder and Chairman, Scientific Advisory Board

Professor, Harvard Medical School and Chief Scientific Officer, Children's Hospital Boston

Dr. Zetter is Chief Scientific Officer at Children's Hospital Boston and Charles Nowiszewski Professor of Cancer Biology at Harvard Medical School. He also serves as a Professor in the Department of Surgery at Harvard Medical School. He is an international leader in tumor progression, cancer diagnosis, metastasis, and angiogenesis. Dr. Zetter’s research focuses on predictive diagnostic tests enabling more effective methods of treating cancer patients. His numerous national and international awards include a Faculty Research Award from the American Cancer Society and the prestigious MERIT award from the U.S. National Cancer Institute. Dr. Zetter serves on multiple editorial boards, including Cancer Biology and Therapy, BioMedCentral and Clinical Cancer Research and Oncology Reports. He has authored more than 150 articles and holds more than 40 patents.

Marsha A. Moses, Ph.D. (Co-Founder)

Professor, Harvard Medical School and Senior Principal Investigator, Children's Hospital Boston

Dr. Marsha Moses is Professor of Surgery at Harvard Medical School and Senior Principal Investigator in the Vascular Biology Program at Children's Hospital Boston. She is a pioneer in the discovery of non-invasive biomarkers that predict disease status, stage and therapeutic efficacy in human cancers. She also established and leads a Urinary Proteomics Initiative at Children’s Hospital Boston. Dr. Moses is an internationally recognized expert in the regulation of tumor angiogenesis, having discovered or co-discovered several tumor angiogenesis inhibitors, a number of which are being developed for clinical use. She has authored over 100 peer-reviewed publications, presented over 100 national and international lectures, and holds 38 patents. Her awards and honors include the American Cancer Society Research Award, the Breast Cancer Research Foundation Award, and the Center for Excellence in Women's Health Research Award from Harvard Medical School.

Martin Fleisher, Ph.D.

Chair, Department of Clinical Laboratories and Chief, Clinical Chemistry Service at Memorial Sloan-Kettering Cancer Center

Dr. Martin Fleisher is Chair, Department of Clinical Laboratories and Chief, Clinical Chemistry Service at Memorial Sloan-Kettering Cancer Center. He is a widely known clinical chemist who is an expert in the areas of tumor markers, critical care laboratory medicine, laboratory automation and robotics, and specific protein analysis in B-cell dyscrasia. He is known for his contributions validating tumor markers and biomarkers for early detection of ovarian cancer and for monitoring how prostate cancer patients respond to treatment. He and his colleagues have also devised tests for estimating breast cancer risk and detecting metastases near the brain. Dr. Fleisher is the author of more than 130 publications and holds five US patent

Kevin R. Loughlin, M.D.

Director of Urologic Research, Division of Urology, Brigham and Women’s Hospital and Professor, Department of Surgery, Harvard Medical School

Dr. Kevin Loughlin is Director of Urologic Research at Brigham and Women’s Hospital, a teaching hospital of Harvard Medical School. He has been actively involved in bladder cancer research and has lectured nationally and internationally on urologic research topics. Dr. Loughlin has a particular interest in bladder cancer markers to facilitate early detection and monitoring of bladder cancer. He has been selected for “Best Doctors in America” and “Top Doctors” by The Center for the Study of Services in Washington D.C. He has published more than 200 articles, abstracts, and letters in publications such as New England Journal of Medicine, Journal of Urology, and Laboratory Medicine.

John C. Reed, M.D., Ph.D.

President & Chief Executive Officer, Burnham Institute for Medical Research

Dr. John C. Reed is President and CEO of the Burnham Institute for Medical Research, a leading non-profit biomedical research institute. Dr. Reed is an active scientist, who has published more papers on the subject of programmed cell death than any other and whose scientific publications have received more citations than any other cell biologist worldwide for the past decade. He has co-founded three biotechnology companies and has been awarded over 50 patents. Dr. Reed currently serves on the editorial boards of over 12 scientific journals. He has also served as an advisor to the National Cancer Institute (NCI), American Cancer Society (ACS), and the American Association for Cancer Research (AACR).